GH1 and neoplasm: However, areas of uncertainty remain including whether treatment with hGH should be delayed by 1 year after completion of tumor/cancer therapy (28), whether the dosing of hGH should be different in this population and whether the overall reassuring safety data are truly applicable to GH-deficient children with cancer predisposing syndromes (6).